Screener
Arbutus Biopharma Corporation ABUS Long-Term Debt
Long-Term Debt at other companies
Other financials
Where this comes from
Reported directly by Arbutus Biopharma Corporation in its filing.
Tagged under the XBRL concept us-gaap:LongTermDebt.
The source filing: Arbutus Biopharma Corporation’s 10-Q, filed May 13, 2026.
- Filed
- May 13, 2026, 7:31 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001447028-26-000021
At March 31, 2026, the Company had an aggregate of $95.2 million in cash, cash equivalents and investments in marketable securities. The Company had no outstanding debt as of March 31, 2026. The Company believes it has sufficient cash resources to fund its operations for at least the next 12 months.
ITEM 1. FINANCIAL STATEMENTS (UNAUDITED)
FAQ
- What is Arbutus Biopharma Corporation's long-term debt?
- Arbutus Biopharma Corporation (ABUS) reported long-term debt of $0 in Q1 2026.
- What does long-term debt mean?
- Bonds, term loans, notes payable, and other borrowings with maturities beyond one year — the primary long-term financing source.
Ask your AI about Arbutus Biopharma Corporation's long-term debt.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude